• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的随机对照多中心临床研究

A randomized placebo-controlled multicentre study of Fuzhenghuayu capsule for prevention of oesophageal variceal bleeding in patients with liver cirrhosis

摘要:

目的 评价扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的临床疗效. 方法 采用随机、对照、双盲、多中心、前瞻性临床研究,181例肝硬化患者,根据食管静脉曲张程度、有无出血史分为3组:食管静脉曲张轻度大组、食管静脉曲张中/重度大组、预防再出血大组.食管静脉曲张轻度大组患者随机分配接受扶正化瘀胶囊和安慰剂治疗;食管静脉曲张中/重度大组患者随机分配接受扶正化瘀胶囊、普萘洛尔联用安慰剂、扶正化瘀胶囊联用普萘洛尔治疗;预防再出血大组患者随机分配接受普萘洛尔联用安慰剂、扶正化瘀胶囊联用普萘洛尔治疗.治疗观察2年后,随访患者至发生终点事件或至2009年2月.主要终点为食管静脉曲张破裂出血,次要终点为任何原因导致的死亡、原发性肝癌、肝移植.用Kaplan-Meier法分析各大组内各组食管静脉曲张破裂出血发生率、生存率的差异. 结果 经中位时间为50个月的随访,食管静脉轻度曲张患者中,扶正化瘀胶囊组累积出血率显著低于安慰剂组(3.4%对比23.7%),差异有统计学意义(x2=4.829,P=0.028).食管静脉中/重度曲张患者中,扶正化瘀胶囊联用普萘洛尔组(联用组)累积出血率显著低于普萘洛尔组(15.2%对比43.6%),差异有统计学意义(x2=6.166,P=0.013);扶正化瘀胶囊组与普萘洛尔组、联用组与扶正化瘀胶囊组之间的累积出血率比较,P值均大于> 0.05,差异无统计学意义.预防再出血患者中,扶正化瘀胶囊联用普萘洛尔组和普萘洛尔组的再出血中位时间分别为(40.00±17.92)个月和(7.00±2.3)个月,两组间累积再出血率比较(44.4%对比24.2%),x2=4.433,P=0.035,差异有统计学意义. 结论 扶正化瘀胶囊能降低肝硬化食管静脉轻度曲张患者累积出血概率;不论是否有食管静脉曲张破裂出血史,扶正化瘀胶囊联用普萘洛尔可降低食管静脉中重度曲张患者累积出血概率.

更多
abstracts:

Objective To evaluate the efficacy of Fuzhenghuayu capsule for the prevention of oesophageal variceal bleeding in patients with liver cirrhosis.Methods A multicentre randomized placebo-controlled trial was conducted.A total of 181 liver cirrhosis patients were enrolled in the study and randomly assigned to different groups according to the level of oesophageal variceal bleeding.Patients with light oesophageal varices received Fuzhenghuayu capsule or a placebo.Patients with medium to heavy oesophageal varices received either Fuzhenghuayu capsule alone,Fuzhenghuayu capsule plus propranolol,or propranolol plus a placebo.Patients with a history of oesophageal variceal bleeding received either Fuzhenghuayu capsule plus propranolol,propranolol alone,or a placebo.For all patients,the treatment lasted 2 years.The primary end point of the study was oesophageal variceal bleeding.The secondary end points were liver cancer,death by any cause,and liver transplantation.Risk of bleeding and survival were statistically assessed.Results The median follow-up time was 50 months.The patients with small oesophageal varices who were treated with Fuzhenghuayu capsule showed a significantly higher cumulative probability of bleeding than their counterparts treated with the placebo (3.4% vs.23.7%,x2-4.829,P =0.028).The patients with medium to heavy oesophageal varices and no history of oesophageal variceal bleeding who were treated with Fuzhenghuayu capsule plus propranolol showed a remarkably higher cumulative probability of bleeding than their counterparts treated with propranolol alone (15.2% vs.43.6%,x2 =6.166,P =0.013).There were no significant differences between the patients treated with Fuzhenghuayu capsule alone and those treated with propranolol alone (P =0.147) or the patients treated with Fuzhenghuayu capsule plus propranolol and those treated with Fuzhenghuayu capsule alone (P =0.147).The patients with history of oesophageal variceal bleeding who were treated with Fuzhenghuayu capsule showed significantly higher cumulative probability of bleeding and median time of bleeding than their counterparts treated with propranolol alone (44.0% vs.24.2% and 40.00 ± 17.92 months vs.7.00 ± 2.35 months; x2 =4.433,P =0.035).There were no significant differences in the cumulative probability of liver cancer and survival among all of the groups.Conclusion Fuzhenghuayu capsule can decrease the cumulative probability of bleeding in cirrhotic patients with light oesophageal varices.For cirrhosis patients with a history of oesophageal variceal bleeding,the combination of Fuzhenghuayu capsule plus propranolol can decrease the cumulative probability of bleeding with median or heavy varices.

More
作者: 肖定洪 [1] 顾杰 [2] 蔡虹 [3] 张琴 [4] 薛冬英 [5] 赵长青 [2] 徐列明 [6]
作者单位: 上海嘉定区中医医院 [1] 201203,上海中医药大学附属曙光医院 肝病研究所 [2] 厦门市中医院 [3] 上海市公共卫生中心 [4] 上海中医药大学附属普陀医院 [5] 201203 上海中医药大学附属曙光医院 肝病研究所;肝肾疾病病证教育部重点实验室、上海市中医临床重点实验室 [6]
期刊: 《中华肝脏病杂志》2014年22卷8期 594-599页 MEDLINEISTICPKUCSCD
栏目名称: 肝纤维化 肝硬化
DOI: 10.3760/cma.j.issn.1007-3418.2014.08.009
发布时间: 2014-09-15
基金项目:
上海市教育委员会重点学科(第五期)建设项目 上海市高校创新团队建设项目 国家中医药管理局中医肝胆病重点学科
  • 浏览:929
  • 下载:196

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷